Finanzen von Ping An Biomedical Co Ltd (PASW)PASWPing An Biomedical Co Ltd

Evaluating the bottom line, Ping An Biomedical Co Ltd maintains a gross margin of 7.54%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 5.60%, while the net margin is 50.30%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PASW converts its operational activities into shareholder value.

In the context of the broader market, PASW competes directly with industry leaders such as JL and TLIH. With a market capitalization of $14.89M, it holds a significant position in the sector. When comparing efficiency, PASW's gross margin of 7.54% stands against JL's 31.19% and TLIH's 24.04%. Such benchmarking helps identify whether Ping An Biomedical Co Ltd is trading at a premium or discount relative to its financial performance.

The company has shown improvement in its gross margin, which increased to 7.54% in Q2 2026 from 2.78% in Q4 2025, and a net margin of 50.30% in Q2 2026, indicating a turnaround in profitability. The current ratio is also strong at 2.54, suggesting good short-term financial health.